Arca
Skip to content
Tools
Tools

CCDC6, RET: Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET

Chimeric protein in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on CCDC6, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved2

  • Selpercatinib
  • Pralsetinib

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        SelpercatinibApprovedEli LillySmall moleculeInhibitorCoiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor21
        PralsetinibApprovedRigel PharmaceuticalsSmall moleculeInhibitorCoiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor12

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
        Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver MutationsSelpercatinibPhase 2Not yet recruitingShanghai Zhongshan HospitalSep 21, 2026
        A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in IndiaSelpercatinibPhase 4Not yet recruitingEli Lilly and CompanySep 16, 2026
        Molecularly Tailored Therapy in Advanced Pancreatic CancerSelpercatinibPhase 2Not yet recruitingHerlev HospitalSep 3, 2026
        Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsPralsetinibPhase 4RecruitingRigel PharmaceuticalsJul 15, 2026
        Response to Neoadjuvant Treatment in Locally Advanced Thyroid CancerPralsetinib, Selpercatinib—RecruitingFujian Medical UniversityFeb 19, 2026
        A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLCPralsetinibNot applicableNot yet recruitingFudan UniversityFeb 18, 2026
        Feasibility Study for Repurposing RET InhibitorsSelpercatinibEarly phase 1Not yet recruitingUniversity of OklahomaAug 28, 2025
        A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene MutationsPralsetinib—Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesJul 3, 2025
        Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyPralsetinib, SelpercatinibPhase 4Not yet recruitingFujian Medical UniversityJun 8, 2025
        Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.PralsetinibPhase 2RecruitingSun Yat-sen UniversityAug 21, 2024
        Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerPralsetinibPhase 2RecruitingWest China HospitalJul 1, 2024
        Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)SelpercatinibPhase 2RecruitingChildren's Hospital of PhiladelphiaJun 13, 2024
        A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid CancerPralsetinib, SelpercatinibPhase 4RecruitingFudan UniversityJan 8, 2024

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3430904, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.